H. Pylori Treatment Failed: What Now?

Failed first-line treatment for H. pylori is frustrating but far from unusual, and it does not mean the infection is untreatable. Roughly one in five people treated with standard triple therapy still test positive afterward, and the next steps depend on why the treatment didn’t work and which drugs were already used. The good news is that second-line and even third-line regimens can still clear the infection in a large majority of cases, especially when antibiotic choices are guided by local resistance patterns or, better yet, by testing the specific strain you carry.

Make Sure Treatment Actually Failed

Before switching to a new regimen, it’s worth confirming the result is real. The urea breath test, one of the most common ways to check for H. pylori after treatment, can give false negatives if you take it too soon after finishing a proton pump inhibitor (PPI). One study found that about a third of infected people temporarily tested negative while still on a PPI, and that false results appeared as soon as one day into PPI therapy.¹ PPIs suppress the bacteria enough to fool the test without actually killing them. The flip side is also true: false positives and false negatives both become more common the longer PPI use continues before testing.²

Guidelines generally recommend waiting at least four weeks after finishing antibiotics and at least two weeks off PPIs before retesting. If your doctor ordered a breath test or stool antigen test while you were still on acid-suppressing medication, or very shortly after stopping, the result might not be trustworthy either way. A retest under proper conditions is a reasonable first move before committing to another round of antibiotics.

Why First-Line Treatment Fails

There is rarely a single reason treatment doesn’t work, and in practice, the causes overlap. But the main contributors break down into a few categories.

Antibiotic Resistance

This is the biggest factor globally. Clarithromycin, one of the two antibiotics in the most common first-line triple therapy, has become progressively less effective as resistance rates climb. The mutations that confer resistance sit in a specific segment of the bacterium’s ribosomal RNA. Studies from Spain, Sudan, and other regions have documented these mutations in a substantial share of clarithromycin-resistant strains, with some populations showing resistance in over a third of isolates.³⁴ If you took clarithromycin-based triple therapy and it didn’t work, there is a good chance the strain you carry was already resistant to clarithromycin before you started.

Metronidazole resistance is also widespread, particularly in developing countries. And fluoroquinolone resistance, which matters for second-line treatment, is rising fast in regions where those drugs are heavily prescribed. In South Korea, for example, quinolone resistance in H. pylori jumped from about 5% to roughly 25% in under a decade.⁵ The pattern is clear: the more a given antibiotic class is used in a population, the faster resistance develops.

Biofilm Formation

H. pylori doesn’t just float around in your stomach acid. It can form biofilms on the gastric lining, essentially encasing itself in a protective matrix that makes antibiotics far less effective. Research on clinical isolates has found that strains producing heavy biofilms are significantly more likely to resist clarithromycin, metronidazole, and levofloxacin. In one study, the risk of levofloxacin resistance was over three times higher in high-biofilm strains compared to low-biofilm strains.⁶ Biofilms also generate resistance mutations more frequently than free-floating bacteria, meaning that treatment itself can inadvertently push remaining bacteria toward becoming harder to kill.

How Your Body Handles the Drugs

The acid-suppressing component of H. pylori treatment, usually a PPI like omeprazole or lansoprazole, is broken down by a liver enzyme called CYP2C19. People vary genetically in how fast that enzyme works. If you’re a fast metabolizer, your body clears the PPI quickly, which means your stomach acid isn’t suppressed as effectively, and the antibiotics have a harder time doing their job in that acidic environment. A systematic review and meta-analysis found that fast metabolizers had roughly two and a half times the odds of treatment failure compared to poor metabolizers. When the analysis was limited to patients who took their pills properly and whose infections were susceptible to clarithromycin, the odds were over four times higher.⁷

Not Finishing the Pills

H. pylori regimens involve taking multiple drugs several times a day for one to two weeks, and the side effects can be unpleasant. Older data showed that eradication rates dropped from about 96% to 69% when patients took only around 60% of their medication.⁸ Regimens with more daily doses and those containing bismuth tend to have higher dropout rates, often because of side effects like nausea, metallic taste, and diarrhea.⁹ If side effects caused you to skip doses or stop early, that alone could explain why the infection persisted.

Standard Second-Line Options

If first-line therapy fails, guidelines recommend switching to a regimen that uses different antibiotics. The two most established options are bismuth-containing quadruple therapy and levofloxacin-based regimens.

Bismuth quadruple therapy combines a PPI with bismuth subsalicylate (or bismuth subcitrate), metronidazole, and tetracycline. It works through a completely different set of antibiotics than standard triple therapy, and H. pylori resistance to tetracycline remains rare in most parts of the world. A meta-analysis comparing rescue regimens found that bismuth quadruple therapy and levofloxacin-amoxicillin triple therapy achieve comparable eradication rates, though bismuth-based regimens tend to produce more side effects.¹⁰

Levofloxacin-based regimens swap the fluoroquinolone in for clarithromycin. Across multiple studies, the average eradication rate with levofloxacin-based rescue therapy runs around 80%, and ten-day courses do better than seven-day ones.¹¹ Extending to 14 days pushes the success rate higher still; one trial in Taiwan reported over 90% eradication with a 14-day levofloxacin course compared to about 76% with a 10-day course.¹² Combining both bismuth and levofloxacin in a quadruple regimen for 14 days has achieved cure rates at or above 90% in patients who failed standard first-line therapy.¹³

The catch with levofloxacin is that fluoroquinolone resistance is spreading rapidly, as the Korean data illustrate. If you live in a region where fluoroquinolone prescribing is common, this option may be less reliable unless susceptibility testing confirms the strain is still sensitive.

When Two Rounds Fail

A second treatment failure narrows the options but doesn’t close them off. This is where rifabutin enters the picture. Rifabutin is a drug originally developed for tuberculosis, and H. pylori rarely develops resistance to it because the bacterium isn’t frequently exposed to this antibiotic class. Rifabutin-based triple therapy, typically combining rifabutin with amoxicillin and a PPI, achieves eradication rates around 80% when used as a third-line salvage regimen.¹⁴ In a study specifically targeting patients carrying strains resistant to both clarithromycin and metronidazole, rifabutin-based therapy succeeded in about 80% of cases, with side effects that were generally mild.¹⁵

Rifabutin can cause bone marrow suppression in a small number of patients, so blood counts are sometimes monitored during treatment. Doctors generally reserve it for patients who have already failed at least two other regimens, in part to avoid promoting resistance to a drug that remains critical for treating tuberculosis.¹⁶

Vonoprazan and Stronger Acid Suppression

One of the most promising developments in H. pylori treatment is the arrival of potassium-competitive acid blockers, particularly vonoprazan. Unlike PPIs, vonoprazan works immediately, provides stronger and more consistent acid suppression around the clock, and its effectiveness isn’t affected by CYP2C19 genetic differences, the same enzyme variation that trips up PPI-based regimens.¹⁷

In first-line treatment, a randomized trial showed that vonoprazan-based triple therapy achieved eradication rates above 95%, compared to roughly 70% with PPI-based triple therapy.¹⁸ A comprehensive meta-analysis of randomized controlled trials confirmed higher eradication rates with P-CAB-based therapy across treatment-naïve patients, different drug durations, and various regimen types.¹⁹

For rescue therapy specifically, a recent multicenter trial compared vonoprazan-amoxicillin dual therapy, vonoprazan-rifabutin-amoxicillin triple therapy, and standard bismuth quadruple therapy in patients who had already failed at least one round. The rifabutin-vonoprazan combination and bismuth quadruple therapy both achieved about 90% eradication. Vonoprazan-amoxicillin dual therapy alone came in lower, around 76%, and failed to show it was as good as bismuth quadruple therapy.²⁰ Vonoprazan is already approved in several countries and is increasingly available, though access varies by region.

Resistance-Guided Treatment

The most effective way to choose the right next regimen is to stop guessing and find out which antibiotics the bacterium is actually resistant to. This used to require an endoscopy with biopsy and a lab culture, which was invasive, slow, and not available everywhere. Newer approaches can detect resistance mutations from a stool sample using PCR-based tests, making susceptibility-guided treatment more practical.

A real-world study using PCR testing of stool samples to guide antibiotic choices achieved a 91% overall eradication rate across nearly 400 patients. Those given resistance-guided bismuth quadruple therapy succeeded in 90% of cases, and those given high-dose amoxicillin-based dual therapy achieved about 95%.²¹ That 91% success rate is a meaningful improvement over the roughly 70-80% you’d expect from empirical second-line therapy, and it comes with the advantage of avoiding unnecessary antibiotics.

If your first treatment failed and your doctor suggests trying another empirical regimen without testing for resistance, it’s worth asking whether susceptibility testing is available. Not every clinic offers stool-based molecular testing yet, but it is becoming more accessible, and the payoff in terms of treatment success can be substantial.

Probiotics as a Sidekick, Not a Replacement

Adding probiotics during H. pylori treatment won’t replace antibiotics, but the evidence suggests they provide a modest boost to eradication rates while significantly reducing side effects, particularly diarrhea. A meta-analysis found that probiotic supplementation alongside standard triple therapy improved eradication odds by roughly 67% and cut the overall rate of adverse effects approximately in half.²² A more recent meta-analysis specifically evaluating probiotics added to bismuth quadruple therapy confirmed the pattern: improved eradication success and significantly fewer side effects, especially diarrhea and nausea.²³

If side effects from the last round contributed to poor compliance, adding a probiotic to the next attempt is a low-risk strategy that may help you tolerate the full course. The benefit appears most consistent in Asian populations and with multi-strain probiotic preparations, but the overall direction of the evidence points toward a real, if moderate, advantage.

Smoking and Treatment Failure

If you smoke, the odds are stacked higher against you. A meta-analysis found that smoking increased the likelihood of eradication failure by about 70%. People who smoked more than five cigarettes a day had roughly two and a half times the failure risk, and continuing to smoke during treatment was associated with about two and a half times the odds of failure compared to not smoking.²⁴ A separate study in a high-risk region of Colombia found smokers had double the probability of treatment failure compared to nonsmokers.²⁵

The mechanism likely involves reduced blood flow to the stomach lining and changes in gastric acid secretion that undermine antibiotic delivery to the bacteria. If you’re about to attempt a second or third round of treatment, quitting or at least pausing smoking during the treatment period could meaningfully improve your chances.

Recrudescence Versus Reinfection

Testing positive again after treatment doesn’t always mean the infection came back from outside. There are two distinct scenarios. Recrudescence means the original infection was never fully eliminated; the bacteria were suppressed below the detection threshold and then bounced back. Reinfection means you cleared the original strain and picked up H. pylori again from a new exposure.

A study in Bangladeshi adults found that recrudescence accounted for most early reappearances. About 14% of successfully treated patients tested positive again within the first three months, but that number came from bacteria that had been temporarily suppressed rather than killed.²⁶ True reinfection was less common, occurring in about 11 out of 105 patients between three and 18 months after treatment, for an annual reinfection rate of around 13%. In developed countries, annual reinfection rates tend to be much lower, often under 2%.

An analysis of breath test results reinforced this. Patients whose post-treatment breath test values hovered near the positive cutoff were more likely to relapse than those with clearly negative results, suggesting the infection had been suppressed rather than eradicated. Once the breath test stayed negative for 12 months, the subsequent reinfection rate was less than half a percent per year.²⁷ The practical implication: if you tested positive shortly after treatment, a more potent regimen has a strong chance of finishing the job. If you tested negative for a long stretch and then turned positive, genuine reinfection is more likely, particularly in areas with high transmission.

Treatment Challenges in Children

Pediatric H. pylori infections face an even tougher resistance landscape. A study of clinical isolates from children found that clarithromycin and metronidazole resistance both exceeded 80%, and nearly three-quarters of the strains were resistant to at least two antibiotics.²⁸ With so few reliable empirical options, susceptibility testing before treatment is even more important in children than in adults.

Early case reports of vonoprazan-amoxicillin dual therapy in children with refractory, multi-drug-resistant H. pylori infections have been encouraging. In a small case series, all treated patients achieved successful eradication and tolerated the regimen well.²⁹ Larger trials are needed, but for children who have failed multiple rounds of conventional therapy, vonoprazan-based regimens may eventually become a realistic option.

High-Dose Dual Therapy for Resistant Strains

When a strain is resistant to both clarithromycin and metronidazole, the standard salvage toolbox shrinks. One approach that has shown promise in this situation is high-dose amoxicillin-based dual therapy, which pairs a PPI (or vonoprazan) with amoxicillin at higher-than-usual doses taken multiple times a day. The logic is straightforward: H. pylori resistance to amoxicillin remains extremely rare worldwide, and maximizing the amoxicillin dose while keeping stomach acid as low as possible creates a hostile enough environment to overcome the infection.

A trial enrolling patients specifically carrying dual-resistant strains compared high-dose dual therapy to quadruple therapy and found similar success rates, with per-protocol eradication of about 84% for dual therapy and 92% for quadruple therapy, a difference that was not statistically significant.³⁰ Dual therapy has the advantage of simplicity, fewer pills, and fewer side effects, which makes completing the full course easier. Pairing this strategy with vonoprazan instead of a conventional PPI may improve results further, given vonoprazan’s superior acid suppression.

Household Transmission and Preventing Reinfection

H. pylori spreads primarily through oral-oral and fecal-oral routes, which means family members and household contacts are the most likely source of reinfection. In high-prevalence settings, reinfection rates after successful eradication can reach double digits annually, as the Bangladeshi study showed. If you live with someone who also carries H. pylori, clearing your own infection while they remain untreated raises the risk that the bacterium comes back.

Testing and treating household contacts is not universally recommended, but some guidelines suggest it in areas with high prevalence or when a patient has experienced repeated treatment failures and reinfection. Basic hygiene measures such as not sharing utensils, good handwashing practices, and safe water sources reduce, but don’t eliminate, the risk. In developed countries with lower background prevalence, the annual reinfection rate after a confirmed clean test at 12 months is low enough that most people don’t need to worry about it, but in regions where the bacterium is ubiquitous, preventing re-exposure is a genuine challenge that deserves attention alongside choosing the right antibiotic regimen.